JPWO2021076554A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021076554A5
JPWO2021076554A5 JP2022522653A JP2022522653A JPWO2021076554A5 JP WO2021076554 A5 JPWO2021076554 A5 JP WO2021076554A5 JP 2022522653 A JP2022522653 A JP 2022522653A JP 2022522653 A JP2022522653 A JP 2022522653A JP WO2021076554 A5 JPWO2021076554 A5 JP WO2021076554A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
cdr3
cdr2
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022522653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551757A5 (https=
JP2022551757A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/055480 external-priority patent/WO2021076554A1/en
Publication of JP2022551757A publication Critical patent/JP2022551757A/ja
Publication of JPWO2021076554A5 publication Critical patent/JPWO2021076554A5/ja
Publication of JP2022551757A5 publication Critical patent/JP2022551757A5/ja
Ceased legal-status Critical Current

Links

JP2022522653A 2019-10-15 2020-10-14 Ｆｌｔ３を標的とする抗体およびその使用 Ceased JP2022551757A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962915120P 2019-10-15 2019-10-15
US62/915,120 2019-10-15
PCT/US2020/055480 WO2021076554A1 (en) 2019-10-15 2020-10-14 Antibodies targeting flt3 and use thereof

Publications (3)

Publication Number Publication Date
JP2022551757A JP2022551757A (ja) 2022-12-13
JPWO2021076554A5 true JPWO2021076554A5 (https=) 2023-10-19
JP2022551757A5 JP2022551757A5 (https=) 2023-10-19

Family

ID=75538063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522653A Ceased JP2022551757A (ja) 2019-10-15 2020-10-14 Ｆｌｔ３を標的とする抗体およびその使用

Country Status (16)

Country Link
US (1) US20240228628A9 (https=)
EP (1) EP4045537A4 (https=)
JP (1) JP2022551757A (https=)
KR (1) KR20220082882A (https=)
CN (1) CN115348972A (https=)
AR (1) AR120222A1 (https=)
AU (1) AU2020366000A1 (https=)
BR (1) BR112022006817A2 (https=)
CA (1) CA3153801A1 (https=)
CL (1) CL2022000927A1 (https=)
CO (1) CO2022004743A2 (https=)
IL (1) IL292259A (https=)
MX (1) MX2022004291A (https=)
PE (1) PE20221256A1 (https=)
TW (1) TWI867066B (https=)
WO (1) WO2021076554A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EP4291233A4 (en) * 2021-02-10 2025-05-21 Wugen, Inc. POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
WO2023023491A1 (en) * 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
WO2023105087A1 (en) * 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
ES2884844T3 (es) * 2015-03-09 2021-12-13 Agensys Inc Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
HK1255234A1 (zh) * 2015-07-16 2019-08-09 塞勒兰特治疗公司 经半胱氨酸取代的免疫球蛋白
CN118772278A (zh) * 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
JP7317718B2 (ja) * 2017-06-02 2023-07-31 ファイザー・インク Ｆｌｔ３を標的にするキメラ抗原受容体
WO2019023097A1 (en) * 2017-07-26 2019-01-31 Smet Pharmaceutical Inc ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
TW201930344A (zh) * 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法

Similar Documents

Publication Publication Date Title
US11591401B2 (en) Anti-CD28 compositions
IL311600A (en) Antibodies targeting BAFF-R and their use
JP2021526844A5 (https=)
IL317912A (en) A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
CA3091764A1 (en) Antibody variable domains targeting cd33, and use thereof
JP7503642B2 (ja) 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法
US20230383012A1 (en) Antibodies that bind pd-l1, pd-l2, and/or cd28
US20210277121A1 (en) Dual targeting antigen binding molecule
JPWO2021076554A5 (https=)
TW202221015A (zh) 單一及雙靶定配體誘導之t細胞銜接體組合物
JPWO2020228825A5 (https=)
US20250043001A1 (en) Anti-cd28 compositions
US20250084179A1 (en) Anti-cd28 x anti-trop2 antibodies
JPWO2019245991A5 (https=)
JP2021524451A (ja) 最適化済みｇｐ４１結合分子及びその使用
JPWO2020191344A5 (https=)
JPWO2023056243A5 (https=)
JPWO2021226163A5 (https=)
US20250084186A1 (en) Anti-cd28 x anti-enpp3 antibodies
JPWO2023056252A5 (https=)
JPWO2022063316A5 (https=)
JPWO2022097061A5 (https=)
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法
WO2025045018A1 (en) Anti-gamma delta tcr antibodies and uses thereof
CN116547306A (zh) 抗cd28和/或抗b7h3组合物